Abstract: The purpose of this study was to evaluate the association of pharmacogenomic factors and clinical outcome in autistic children and adolescents who were treated with risperidone for long periods. Eighty-two autistic subjects diagnosed with DSM-IV and who were treated with risperidone for more than 1 year were recruited. Pharmacogenomics and clinical outcome (CGI-I, aggressive, overactivity and repetitive score) were evaluated. Almost all patients showed stable symptoms on aggressive behaviour (89.02%), overactivity (71.95%), repetitive (70.89%) behaviour and all clinical symptoms (81.71%). Only 4.48% of patients showed minimally worse CGI-I score. Patients in the non-stable symptom group had DRD2 Taq1A non-wild-type (TT and CT) frequencies higher than the clinically stable group (p = 0.04), whereas other gene polymorphisms showed no significant association. Haplotype ACCTCAT (rs6311, rs1045642, rs1128503, rs1800497, rs4436578, rs1799978, rs6280) showed a significant association with non-stable clinical outcome (v 2 = 6.642, p = 0.010). Risperidone levels showed no association with any clinical outcome. On the other hand, risperidone dose, 9-OH risperidone levels and prolactin levels were significantly higher in the non-stable compared to the stable symptom group (p = 0.013, p = 0.044, p = 0.030). Increased appetite was the most common adverse drug reaction and associated with higher body-weight, whereas it was not significantly associated with genetic variations and non-genetic information. In conclusion, risperidone showed efficacy to control autism, especially aggressive symptoms in long-term treatment. However, Taq1A T -carrier of dopamine 2 receptor gene -is associated with non-stable response in risperidone-treated patients. This study supports pharmacogenomics testing for personalized therapy with risperidone in autistic children and adolescents.
Autism is a disease of neuronal developmental abnormality. The main symptoms are impairment in social interaction and communication skills, repetitive behaviours and restricted interests. However, many associated symptoms were found in autism because of complexity of this disorder, such as hyperactivity or inattention, aggression, repetitive or motor stereotypies [1] . Recently, the U.S. Food and Drug Administration approved two drugs, risperidone and aripiprazole, for pharmacological treatment of autism, especially for patients presenting with severe irritability symptoms [2] .
Risperidone is an atypical antipsychotic. It is an antagonist for the dopamine type 1 (D 1 , D 5 ) and the dopamine type 2 family (D 2 , D 3 and D 4 ) receptors. Moreover, it is also a high-affinity antagonist for the serotonin type 2 (5HT 2 ), a 1 and a 2 adrenergic and H 1 histaminergic receptors. Risperidone blocks the mesolimbic pathway, the prefrontal cortex limbic pathway and the tuberoinfundibular pathway in the central nervous system. Thus, it can increase prolactin secretion causing sexual side effects, such as galactorrhea, infertility and gynaecomastia [3] . P glycoprotein (P-gp) is highly expressed in the blood-brain barrier and plays an important role in the efflux of drugs including risperidone out of the brain [4] . Risperidone is extensively metabolized in the liver by the enzyme cytochrome P450 2D6 (CYP2D6) and to a lesser extent by CYP3A4. The major metabolite is 9-hydroxyrisperidone which is an active metabolite.
Studies of risperidone in autistic patients showed that risperidone was an effective treatment for the management of core symptoms of autistic disorder and improved the clinical global impression. However, some patients had minimal improvement or no response to this treatment [5] [6] [7] . Thus, variations in factors involved in the mechanism of action of risperidone may affect the efficacy of this drug.
Genetic variation is one of the factors that have been widely studied in drug responses. The variation of genes encoding drug metabolism, drug transporters and drug target proteins can cause an alteration of pharmacological treatment outcome. There are many studies of pharmacogenomics that show associations with risperidone efficacy and drug levels. For example, genetic polymorphisms of CYP2D6, CYP3A5 and MDR1 play a role in the pharmacokinetics of risperidone [8] [9] [10] [11] . However, there are controversial results and many studies have small sample sizes. Almost all research focused on schizophrenic patients and healthy subjects without looking at the effect of genetic polymorphisms on clinical outcome. Two pharmacogenomics studies of risperidone showed the treatment outcome in autism spectrum disease (ASD). One study of CYP2D6 polymorphisms in risperidone-treated ASD patients showed an association with treatment response and adverse drug reactions (ADRs). However, the results did not show a statistically significant difference due to small sample size [12] . Another study examined the effect of transporter, dopamine and serotonin gene polymorphisms on risperidone efficacy and ADRs in autism [13] . However, almost all studies focused on the initial response in short periods.
Thus, the purpose of this study was to evaluate the association of pharmacogenomic factors and clinical outcome in autistic children and adolescents who were treated with risperidone for longer periods. Candidate genes that play a role in pharmacokinetics (ABCB1 and CYP2D6) and pharmacodynamics of risperidone (DRD2, DRD and HTR2A) were selected for analysis. Genetic variations of these candidate genes may exert significant effects on risperidone efficacy in autistic children and adolescents.
Methods
Subjects. This prospective cohort study of pharmacogenetics and clinical outcome was performed at Yuwaprasart Waithayopathum Child Psychiatric Hospital, Samut Prakan, Thailand, between 2015 and 2016. Thai autistic children and adolescents who were regularly followed up and received risperidone for more than 1 year were considered eligible to be enrolled in the study. Eighty-two subjects were diagnosed according to DSM-IV criteria and were evaluated for CGI total score, aggressive score, overactivity score and repetitive score. Information on demographics data was collected from medical charts. The patients' compliance was confirmed by the parents or main caregivers. This cross-sectional study was approved by the ethics committee of Ramathibodi Hospital, Mahidol University, Bangkok, Thailand. All participants received a complete description of the study before giving written informed consent.
Treatment outcome evaluation. Treatment results were evaluated using The Clinical Global Impression -Improvement scale (CGI-I) score, and patients scored on a four-point scale for each of aggression, overactivity and repetitive behaviours. Score 0 means no symptoms and score 4 represents the highest severity of symptoms. Aggression is scored as severity multiplied by frequency.
Almost stable clinical symptoms patients were defined as having a 0 score for aggression, overactivity and repetitive symptoms, respectively. Overall stable clinical outcome was defined as the improvement of CGI and stability in the main aggression score. Thus, patients who did not improve and had symptoms (CGI = 5 or CGI = 4 and aggression, overactivity, repetitive symptoms score ≥1) were grouped as non-stable symptoms. Patients who presented with clinical improvement but still had aggressive symptoms (CGI = 1-3 and aggressive ≥1) were classified as non-stable also.
Sample preparation and DNA extraction. Blood samples for genotyping and drug plasma level measurement were collected from participants into EDTA tubes on the clinical evaluation date before the morning dose of risperidone. Whole blood from the EDTA tube was used for DNA extraction by MagNA Pure Compact (Roche Applied Science, Penzberg, Germany). DNA concentrations and purity were measured by NanoDrop spectrophotometer at wavelength 260 nm (Thermo Fisher Scientific, Wilmington, DE, USA).
Genotyping. Polymorphism of DRD2 rs1800497 (Taq IA), and rs1799978 (-241A>G), DRD3 rs6280 (25T>C), and HTR2A rs6311 (-1438G>A) were genotyped using the TaqManâ SNP Genotyping assay (Life Technologies, Camarillo, CA, USA). Drug transporter ABCB1 rs1045642 (3435C>T), rs2032582 (2677G>T/A) and rs1128503 (1236C>T) were genotyped using the TaqMan â Drug
Metabolism Genotyping assay (Life Technologies, Camarillo, CA, USA). CYP2D6 polymorphisms were genotyped using multiplex polymerase chain reaction (PCR) and multiplex allele-specific primer extension (ASPE) by xTAGâ CYP2D6 Kit v3 (Luminex Molecular Diagnostics, Inc., Toronto, Ontario, CA). Genotype data analysis was performed on a Luminexâ 100/200 TM analyser using xPONENT 3.1 or IS 2.3 software. This method has been described by us previously [14] . Predicted phenotypes for various combinations of CYP2D6 alleles detected by the xTAG CYP2D6 Kit v3 were classified by activity score from Gaedigk et al.,
2008.
Assay of plasma RIS and 9-OH RIS concentrations. Plasma concentrations of risperidone and its metabolite, 9-hydroxyrisperidone were measured using the liquid chromatography-mass spectrometrymass spectrometry (LC-MSMS) method, as previously published [15] .
Statistical analysis. After testing for normality, a chi-square was used to test the distribution of ordinal data among groups. A Mann-Whitney U-test was used to compare between two groups, and a Kruskal-Wallis test was used to make comparisons among three groups for continuous data. p values <0.05 were considered statistically significant. Statistical analyses were performed using SPSS version 18.0 (SPSS Inc., Chicago, IL, USA).
The Hardy-Weinberg equilibrium, allele, genotype frequencies of all candidate SNPs, linkage disequilibrium (LD) coefficients (D'), haplotype blocks and haplotype-associated clinical outcome were analysed using the Haploview program v4.2 (Broad Institute, Cambridge, MA, USA).
Results
The general demographic data including diagnosis, medications and risperidone levels of 82 autistic patients (male 90.24%, female 9.76%) are shown in Table 1 . The median age was 11 years (IQR: 9.00-14.00), and median duration of risperidone used was 67.90 months (IQR: 52.53-90.93). Almost all patients were diagnosed with autistic disorder (91.36%). About 6% were pervasive developmental disorder NOS (PDD-NOS). Only 1.23% were Rett's disorder and Asperger's disorder. The predominant additional psychiatric disorder was attention deficit hyperactivity disorder (ADHD) (23.17%). Fifty-two patients (64.20%) also received comedications in this study. The frequent concomitant medications were methylphenidate (n = 29; 35.37%), sodium valproate (n = 18; 21.95%) and sertraline (n = 5; 6.10%). The median concentration of risperidone was 0.94 ng/ml (IQR: 0.25-4.06), and 9-OH risperidone was 8.08 ng/ml (IQR: 3.88-20.13), whereas active moiety concentration was 9.60 ng/ml (IQR: 4.19-24.73).
Clinical outcome.
Aggressive score, overactivity score, repetitive score and CGI-I score are shown in Table 2 . Almost stable clinical symptoms patients were found to amount to 89.02%, 71.95% and 70.89% for aggression, overactivity and repetitive symptoms, respectively. The patients showed much improved (4.48%), minimally improved (76.12%), no change (14.92%) and minimally worse (4.48%) for the CGI-I score. Sixty-seven patients (81.71%) showed stable clinical symptoms, and 15 patients (18.29%) were classified as non-stable.
Genotype frequencies and the association with clinical outcome. Genotype and allele frequencies of pharmacokinetics (ABCB1; 3435C>T, 2677G>T/A, 1236C>T) and pharmacodynamics (DRD2; Taq-SNP (C/T), -241A>G, Taq 1A, DRD3; 25T>C, and HTR2A; -1438G>A)-altering polymorphisms for risperidone are listed in Table 3 . The association between these gene polymorphisms and overall clinical outcome, aggression, overactivity and repetitive symptoms are shown in Table 2 . Only DRD2 Taq 1A was significantly associated with overall clinical outcome. Patients in the non-stable symptom group had DRD2 Taq1A non-wild-type (TT and CT) frequencies higher than the clinically stable group (p = 0.048). No other pharmacokinetics and pharmacodynamics genetic polymorphisms were significantly associated with any clinical symptoms in this study. Interestingly, there was no patient with HTR2A -1438G>A wild-type in all non-stable symptoms. However, there was no significant association due to small sample sizes.
Association between CYP2D6 genotype frequencies, activity scores and predicted phenotype and clinical outcome is shown in Table 4 . The major genotype frequencies for CYP2D6 in our study were *1/*10 (32.93%) and *10/*10 (28.05%), which decreased the enzyme activity. Moreover, non-functional CYP2D6 alleles, *4 and *5, were also detected. However, there was no significant difference of CYP2D6 genotype in stable and non-stable clinical outcome groups (p = 0.953). Predicted phenotypes for CYP2D6 were classified by activity scores. Three predicted phenotypes (UM, EM and IM) were found in this study. There was no significant association of CYP2D6 activity scores (p = 0.818) or predicted phenotype (p = 0.464) with clinical outcome. However, CYP2D6 activity score showed a significant effect on risperidone level and metabolic ratio of risperidone to its metabolite (p = 0.019, and p = 0.041,) as shown in Table 5 .
Haplotype block and haplotype analysis are shown in Fig. 1 and Table 6 . Haplotype ACCTCAT (rs6311, rs1045642, rs1128503, rs1800497, rs4436578, rs1799978, rs6280) was significant associated with non-stable clinical outcome (v 2 = 6.642, p = 0.010). Association of candidate pharmacokinetic and pharmacodynamic genetic polymorphisms for risperidone treatment and clinical symptoms. 
Discussion
This study showed the efficacy of risperidone to control overall autistic symptoms during a long duration of treatment (about 6 years). Patients who had stable clinical symptoms in this study amounted to 81.71%. A previous study showed that 10 of 11 pervasive developmental disorder subjects responded with risperidone treatment without loss of effectiveness when continued for 12 months [16] . A study of 1.2 mg risperidone treatment in children and adolescents with autism for 1 and 6 months showed that patients showed overall significant clinical improvement [17] . In our study, the efficacy was focused on stable symptoms and especially aggressive symptoms, in long-term treatment, not on initial responses as shown in previous studies. Thus, the low risperidone dose in this study resulted in stabilized symptoms. Moreover, the CGI score for this study generally showed "minimally improved" or "no change" in contrast to previous studies. Because of the long duration of treatment, the number of patients who had "very much improved" or "much improved" CGI scores was lower than in previous studies [6, 7] . However, the efficacy was the same due to the stable aggressive symptoms. The candidate gene polymorphisms (ABCB1; 3435C>T, 2677G>T/A, 1236C>T, DRD2; Taq-SNP (C/T), -241A>G, Taq 1A, DRD3; 25T>C, and HTR2A; -1438G>A) studied in our population showed similar frequencies as the Han-Chinese population from the Hap-Map project database. These data indicate similarity in ethnicity of Thai and Han-Chinese for this gene panel.
This study showed a role of DRD2 Taq 1A T (A1) allele for the non-stable symptom. Risperidone is a high-affinity dopamine type 2 receptor antagonist [18] . Thus, the alteration of this receptor might affect drug response. The impact of DRD2 Taq 1A polymorphisms on the density of the dopamine D2 receptors remains controversial. Some studies report that A1 allele affects dopamine D2 receptor expression by decreasing density of the receptor [19] . However, other studies did not find this association [20] . The A1 allele in our study seems to indicate a reduction of dopamine receptors because it showed an association with non-stable symptoms. The decrease in dopamine receptors is speculated to involve less risperidone binding to the D2 receptor and therefore low efficacy. In contrast, other studies showed that Taq 1A polymorphism had no effect on therapeutic efficacy of risperidone in schizophrenia patients [21, 22] . However, our study showed results in accordance with a study of prolactin and DRD2 polymorphism. Prolactin concentrations in patients with the A1 allele were previously reported to be significantly lower than carriers of the other allele, indicating low D2 receptor density [23] .
P-gp is highly expressed in the blood-brain barrier and plays an important role in the efflux of drugs out of the brain. ABCB1 or multidrug resistance 1 (MDR1) gene encodes for ABCB1 transporter or P-gp [4] . Several pharmacogenomic studies of risperidone report an association between ABCB1 polymorphisms and risperidone pharmacokinetics [8, 10, 24] . Furthermore, polymorphisms of ABCB1 show an association with risperidone response in schizophrenia [25] and autistic patients [13] . In this study, we did not find any association of ABCB1 polymorphisms and risperidone efficacy. The patients in this study took risperidone for a long duration leading to a stable dose and stable risperidone concentrations both in the brain and in the plasma. Under these conditions, P-gp did not show a significant effect on risperidone response in this study.
Serotonin 2A and dopamine type 3 receptors also play a role in the activity of risperidone. One pharmacogenetic study of risperidone therapy in autism showed an association of HTR2A; -1438G>A, and DRD3; 25T>C with drug response [13] . In contrast, we did not find any association of these two single SNPs with risperidone response, which may be due to small sample size. Moreover, the function for these SNPs is inconclusive and should be studied further. CYP2D6 plays a major role for risperidone metabolism. The major genotype for CYP2D6 in our study was *1/*10 and *10/*10, similar to a previous study from our group [14] . There was no significant association between CYP2D6 genotypes, activity scores and predicted phenotype with clinical outcome, as was reported in other previous studies of schizophrenia patients [11, 26] . In contrast, one study in autism found that ultra-rapid metabolizer patients were non-responders and poor metabolizer patients were responders [12] . However, the results did not show a statistically significant difference due to small sample size. Although risperidone and its metabolite showed some difference in pharmacokinetics and pharmacodynamics properties [27] [28] [29] , the response was not significantly different [11, 26] . Active moiety concentration, the sum of RIS and 9-OH RIS, plays a major role in efficacy of risperidone. In this study, patients received risperidone for a long time, leading to stable levels of active moiety. However, active moiety did not show a significant difference between the stable and non-stable groups. Thus, clinical outcome did not differ between CYP2D6 variations. On the other hand, CYP2D6 activity score showed a significant effect on risperidone level and metabolic ratio of risperidone to its metabolite. This result confirmed the effect of CYP2D6 variation on enzyme activity, as shown in our previous study [14] . The ratio for each CYP2D6 activity score might be used as a genetic factor to calculate the active moiety from the risperidone dose. Thus, further studies could use this ratio to find the optimal dose depending on CYP2D6 activity. However, inaccuracy of classifying CYP2D6 polymorphism function might lead to misinterpretation of outcome. Even though this study classified CYP2D6 function by activity score, some genotypes, *1/*10, Dup, were not correctly determined. The method to detected CYP2D6 polymorphisms in this study was inaccurate to determine the duplicated CYP2D6 allele in heterozygous samples because it could not identify which allele had the duplication or multiplication. Haplotype ACCTCAT (rs6311, rs1045642, rs1128503, rs1800497, rs4436578, rs1799978, rs6280) showed an association with non-stable clinical symptoms, even though the analysis of some single SNPs did not show the association. High serotonin 2A receptor density (rs6311 A allele) [30] and high dopamine 2 receptor density (rs1799978 A allele) [31] may cause insufficient risperidone blockade of these receptors and non-stable clinical symptoms. Furthermore, low binding affinity of risperidone for D2 and D3 receptors (T allele of rs1800497 and rs6280) [19, 32] may have resulted in nonstable clinical symptoms after risperidone treatment. This result illustrates the effect of genetic variation on quantity and quality of receptors and drug response. However, this haplotype showed a low frequency.
Unstable clinical symptoms, especially aggression in this study, caused the use of higher risperidone dose in the nonstable symptom group. The optimal dose to control symptoms for this study was 0.65 mg/day, which was lower than in previous studies [16, 17, 33] , which may be caused by long-term use (see above). Moreover, prolactin levels were also significantly higher in the non-stable than stable symptom group. High levels of prolactin were associated with aggression and hostility. The previous studies found that women with higher prolactin levels were more hostile than women with normal levels of prolactin [34, 35] . Prolactin that binds to its receptors in the hypothalamus might be related to the control of aggression in human beings [36] . Risperidone dose and DRD2 variation were found to be associated with high prolactin levels in previous studies [23, 37] . On the other hand, prolactin levels in this study showed only an association with HTR2A polymorphism but not with DRD2 polymorphisms. The mechanism of serotonin-induced prolactin response is unclear, but it has been suggested that activation occurs via the 5-HTR2A receptors [38] . High serotonin 2A receptor density (-1438A) [30] may cause an increase in serotonin-induced prolactin response, leading to high prolactin levels. This might explain the effect of high prolactin levels in the non-stable clinical outcome group in this study.
The common ADR was increased appetite, which was associated with higher body-weight, as was also previously reported [5, 7] . The mechanisms of risperidone induction of appetite were described in many ways. Receptors for neurotransmitters (HTR2C, H1 and ɑ1), neuropeptides (leptin, ghrelin and neuropeptide Y) and neuroendocrine mechanisms (insulin and prolactin) seem to be involved in this ADR [39] . However, the increase in appetite did not associate with dose and drug concentrations in this study because of low risperidone dose, which also may be the explanation for not having found extrapyramidal ADRs and other ADRs. Further study should measure weight status before receiving risperidone to analyse weight change during risperidone treatment. Furthermore, changing of lipid profile, insulin levels and prolactin levels should be investigated to determine the effect of risperidone on metabolic status.
Finally, low-dose risperidone (0.65 mg/day) showed efficacy to control autism, especially aggressive symptoms and displayed non-serious ADRs in long-term treatment.
Polymorphism of dopamine 2 receptor genes and prolactin level play a role in risperidone efficacy. However, this study has some limitations that should be considered when interpreting the results. Firstly, the small number of patients, particularly in the non-stable symptom group, limited the comparison of many candidate genes in this study. Secondly, this naturalistic nature of this study led to some uncontrolled factors, such as compliance or food intake. Thirdly, one time-point for collection of data in this cross-sectional study may diminish the evaluating efficacy of long-term treatment. However, some patients showed behaviour problems even though they received the medication for a long time. A further longitudinal study would show the benefit of this evaluation. Moreover, lack of clarity regarding the function of some SNPs may limit interpretation of the results. Future works should investigate a larger group of patients and analyse both genetic and nongenetic factors with drug response. The other polymorphisms in DRD2, DRD3, DRD4 and HTR2A should be analysed. Moreover, neuroendocrine hormone which is associated with autism should also be analysed. These results will be helpful to clinicians by providing information regarding risperidone dosing and levels required to control autistic symptoms and highlight important factors that should be looked at in autistic children treated with risperidone.
